References

10.1002/cncr.29795

10.1002/cncr.29795 · External reference

Nasopharyngeal carcinoma

10.1016/s0140-6736(19)30956-0 · 2019 · External reference

10.3322/caac.21834

10.3322/caac.21834 · External reference

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

10.1016/s1470-2045(21)00302-8 · 2021 · External reference

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

10.1038/s41591-021-01444-0 · 2021 · External reference

Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial

10.1001/jamaoncol.2020.1808 · 2020 · External reference

Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma

10.1016/j.oraloncology.2023.106583 · 2023 · External reference

Efficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study

10.1016/j.radonc.2024.110687 · 2025 · External reference

Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era

10.6004/jnccn.2024.7086 · 2025 · External reference

Radiotherapy, immunity, and immune checkpoint inhibitors

10.1016/s1470-2045(24)00075-5 · 2024 · External reference

10.1200/jco-25-02726

10.1200/jco-25-02726 · External reference

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

10.1016/s1470-2045(20)30737-3 · 2021 · External reference

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial

10.1001/jamaoncol.2021.1683 · 2021 · External reference

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

10.1016/j.annonc.2022.10.006 · 2023 · External reference

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

10.1200/jco-25-00036 · 2025 · External reference

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

10.1016/s1470-2045(21)00149-2 · 2021 · External reference

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

10.1056/nejmoa2032125 · 2021 · External reference

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

10.1200/jco.21.01308 · 2022 · External reference

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

10.1136/jitc-2020-000867 · 2020 · External reference

The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis

10.1016/j.ijrobp.2021.07.1695 · 2021 · External reference

The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis

10.1016/j.radonc.2022.01.003 · 2022 · External reference

Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors

10.1038/s41467-022-34676-w · 2022 · External reference

A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

10.1038/s43018-022-00450-6 · 2022 · External reference

High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial

10.1016/j.ijrobp.2023.04.029 · 2023 · External reference

Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas

10.1016/s1470-2045(25)00327-4 · 2025 · External reference

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(25)01850-1 · 2026 · External reference

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

10.1056/nejmoa2415434 · 2025 · External reference

A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors

10.1002/cac2.12068 · 2020 · External reference

Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

2017 · External reference

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

2017 · External reference

Combining radiotherapy and cancer immunotherapy: a paradigm shift

10.1093/jnci/djs629 · 2013 · External reference

Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study

10.1016/j.ijrobp.2020.08.045 · 2021 · External reference

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial

10.1001/jama.2025.1132 · 2025 · External reference